Shaily Engineering Plastics Ltd Share Price – NSE /  BSE

Plastic products, Small Cap

Shaily Engineering Plastics announced that its strategic partner Orbicular Pharmaceutical Technologies in partnership with its Customer has launched a generic version of Semaglutide injection in Canada, incorporating Shaily's proprietary spring-driven ShailyPen Neo? pen platform. The combination product has been commercially available in India since March 2026 and has received USFDA Tentative Approval.

ShailyPen Neo? is among a rare class of commercially available spring-driven pen injectors globally ? a high-performance, variable and fixed dose platform offering full compatibility with ISO-standard 3 mL cartridges (3 mL and 1.5 mL fill). Shaily's role in this program relates to full design and development, and manufacturing and supply of the device components used in the approved combination product.

Shaily Engineering Plastics has allotted 40,155 equity shares under ESOP on 19 May 2026. With this allotment, the paid up equity share capital has increased to Rs. 9,19,90,496 divided into 4,59,95,248 equity shares of Rs. 2/- each.

Shaily Engineering Plastics announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.

Net profit of Shaily Engineering Plastics rose 40.47% to Rs 40.16 crore in the quarter ended March 2026 as against Rs 28.59 crore during the previous quarter ended March 2025. Sales rose 8.72% to Rs 236.82 crore in the quarter ended March 2026 as against Rs 217.83 crore during the previous quarter ended March 2025.

For the full year,net profit rose 82.46% to Rs 169.91 crore in the year ended March 2026 as against Rs 93.12 crore during the previous year ended March 2025. Sales rose 25.91% to Rs 990.67 crore in the year ended March 2026 as against Rs 786.80 crore during the previous year ended March 2025.

Powered by Capital Market - Live News